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Abstract
Background: Helicobacter pylori, a lifelong and typically asymptomatic infection of the stomach, profoundly alters gastric
immune responses, and may benefit the host in protection against other pathogens. We explored the hypothesis that H.
pylori contributes to the control of infection with Mycobacterium tuberculosis.
Methodology/Principal Findings: We first examined M. tuberculosis-specific IFN-c and H. pylori antibody responses in 339
healthy Northern Californians undergoing routine tuberculin skin testing. Of 97 subjects (29%) meeting criteria for latent
tuberculosis (TB) infection (LTBI), 45 (46%) were H. pylori seropositive. Subjects with LTBI who were H. pylori-seropositive had
1.5-fold higher TB antigen-induced IFN-c responses (p = 0.04, ANOVA), and a more Th-1 like cytokine profile in peripheral
blood mononuclear cells, compared to those who were H. pylori seronegative. To explore an association between H. pylori
infection and clinical outcome of TB exposure, we evaluated H. pylori seroprevalence in baseline samples from two high risk
TB case-contact cohorts, and from cynomolgus macaques experimentally challenged with M. tuberculosis. Compared to 513
household contacts who did not progress to active disease during a median 24 months follow-up, 120 prevalent TB cases
were significantly less likely to be H. pylori infected (AOR: 0.55, 95% CI 0.0.36–0.83, p = 0.005), though seroprevalence was
not significantly different from non-progressors in 37 incident TB cases (AOR: 1.35 [95% CI 0.63–2.9] p= 0.44). Cynomolgus
macaques with natural H. pylori infection were significantly less likely to progress to TB 6 to 8 months after M. tuberculosis
challenge (RR: 0.31 [95% CI 0.12–0.80], p= 0.04).
Conclusions/Significance: H. pylori infection may induce bystander effects that modify the risk of active TB in humans and
non-human primates. That immunity to TB may be enhanced by exposure to other microbial agents may have important
implications for vaccine development and disease control.
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Introduction
The microbes that colonize the human host are diverse and
demonstrate geographic and temporal variability. This variability
is exemplified by H. pylori infection, a gastric mucosal pathogen
that comprises part of the ‘‘normal flora’’ in much of the
developing world, but has receded over time in higher socioeco-
nomic regions of the world. H. pylori has been colonizing humans
for at least 50,000 years [1]. Why its prevalence varies so
dramatically based on socioeconomic status is not known but may
relate to antimicrobial use, improved household and environmen-
tal sanitation, and decreased crowding. Another hypothesis,
however, is that H. pylori infection provides a survival benefit
against challenges present disproportionately in poorer geographic
regions. By boosting mucosal and systemic immunity, the
organism may limit the consequences of other infectious exposures
[2,3] and selectively promote survival of H. pylori infected hosts.
One third of the world’s population is latently infected with the
intracellular pathogen M. tuberculosis [4]. Following exposure, the
organism elicits an IFN-c-driven, cellular immune response,
causing infected macrophages to be sequestered within organized
lung granulomas [5,6]. In approximately 90% of humans, the host
immune response controls but does not eliminate the infection,
preventing progression to active disease throughout the host’s
lifespan [7]. Those infected with M. tuberculosis but with no
symptoms of disease are referred to as latently infected. Although
risk of active tuberculosis is significantly elevated in immunocom-
promised hosts (e.g., those with HIV infection [8] or treated with
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immunosuppressants [9]), the great majority of individuals who
develop active TB do so in the absence of known immunocom-
promise. The nature of protective immunity remains unknown.
M. tuberculosis and H. pylori are the most prevalent bacterial
pathogens worldwide. In much of the world’s population, these
obligate human infections coexist throughout most of the life span,
continuously interacting with the host immune system without
causing disease. Almost nothing is known about the crosstalk of
these infections and whether one infection affects the clinical
manifestations of the other. The few studies examining an
epidemiologic linkage between H. pylori and tuberculosis have
yielded conflicting results [10,11,12]. While conducting a study of
TB diagnostics in a population that had been tested for H. pylori,
we fortuitously identified differences in interferon gamma (IFN-c)
and other cytokine responses to M. tuberculosis antigens in H. pylori-
infected and uninfected hosts. To explore this relationship further,
we compared rates of H. pylori seropositivity in blood samples from
TB cases and household contacts recruited from TB case-contact
studies carried out in The Gambia [13] and Karachi, Pakistan
[14]. We also compared outcome of M. tuberculosis challenge [15]
in macaques with and without naturally-acquired H. pylori
infection. Our results support further investigations into the
contribution of H. pylori infection to the protective immune
response to TB infection.
Materials and Methods
Overview
Three distinct studies were undertaken sequentially. Studies
involving human subjects or samples were conducted in
accordance with principles expressed in the Declaration of
Helsinki. Non-human primate studies were conducted in accor-
dance with the United States Animal Welfare Act and the Guide
for the Care and Use of Laboratory Animals of the Institute for
Laboratory Animal Research, National Academies of Science.
Each study was approved by the appropriate Institutional Review
Boards as described.
(1) IFN-c responses to TB antigens in Northern
Californians with and without H. pylori infection. The
Stanford Infection and Family Transmission [SIFT] study was
established in 1999 to evaluate incidence of H. pylori infection
within predominately immigrant communities of the South
Peninsula, San Francisco Bay. Since 2003, we have tested
concurrently for latent M. tuberculosis infection. Data used in this
report include 339 healthy residents of Santa Clara County, CA
who gave written consent between September 2003 and May 2006
to provide blood for QuantiFERON-TB GOLD (in-tube) IFN-c
release assay (Cellestis, Ltd, Melbourne, Australia), as well as for
H. pylori and other infectious disease testing, at the time of routine
tuberculin skin test (Table 1). Children under 2 years of age, and
individuals with history or symptoms of active tuberculosis were
not recruited. The population is predominately Hispanic,
including 50% born in a TB endemic country (90% Latin
America). The study was approved by the Institutional Review
Boards of Stanford University and the Santa Clara Valley Medical
Center.
(2) H. pylori sero-prevalence in human tuberculosis case-
contact cohorts. De-identified plasma samples obtained at a
baseline screening visit were recruited from the specimen banks of
tuberculosis case-contact studies conducted by the Medical
Research Council, The Gambia, West Africa [16] and the Aga
Khan University, Karachi, Pakistan [14], respectively. Each study
enrolled households based on an index case of active tuberculosis,
and assessed participants clinically for at least 24 months from
baseline, with overall rates of activation 1.1% (The Gambia [13])
and 6.4% (Karachi [14]) previously reported. Active TB was
ascertained by symptoms, chest X-ray and AFB smear and culture
in The Gambia [16], and by symptoms, chest X-ray and AFB
smear in Pakistan [14]. Baseline TB infection was determined by
positive ($10 mm) TST and/or ELISPOT in The Gambia [17]
and by positive TST ($10 mm in Pakistan [14]. Blood samples
recruited for the present studies were from HIV-negative subjects
with blood drawn before the onset of treatment of a TB prevalent
or incident case.
Sampling proportions and baseline characteristics of subjects
whose samples were selected for analysis are shown in Table S4.
From The Gambia, 549 samples were randomly selected in 2
phases from a pool of 2626 eligible samples (Figure 1A). The first
group consisted of samples from 100/295 eligibleTB cases
(household index cases) and 100/2271 eligible age- and sex-
matched household contacts who were TB infected at baseline and
known to have remained disease-free for at least 2 years of follow-
up (nonprogressors). Samples from Gambian TB cases were
proportionately representative of Gambian TB isolates (approxi-
mately 40% M. africanum and 60% M. tuberculosis [18]). The second
sampling phase included samples from 29/32 subjects who
developed active TB 3–47 months from baseline, and 320 age-
and sex-matched nonprogressors. The study was approved by the
Institutional Review Boards of Stanford University and the MRC
Ethics Committee. A complete sample was obtained from the
Pakistan cohort (Figure 1B), including 20 index TB cases, 8
incident TB cases ascertained 3–49 months from baseline, and 93
Table 1. Population characteristics: Northern California H.
pylori/LTBI studies.
Characteristic
Total
(n = 339)
H. pylori+
(n = 101)
H. pylori2
(n = 238)
Age, mean, range 28 (3–80) 31 (8–80) 27 (3–75)
2–17 y 113 (33) 21 (21) 92 (39)
$18y 226 (67) 80 (78) 146 (61)
Sex
Male 126 (37) 48 (48) 78 (33)
Female 213 (63) 53 (52) 160 (67)
Hispanic ethnicity 238 (70) 90 (89) 148 (62)
Foreign-born1 167 (49) 73 (72) 94 (40)
Hepatitis A total IgG 212 (63) 79 (78) 133 (56)
Mycobacterial infections/exposures
BCG scar (present) 114 (34) 47 (47) 67 (28)
History TB exposure 46 (14) 20 (20) 26 (11)
Latent TB infection2
TST+ 82 (24) 40 (40) 42 (18)
QFT+ 48 (14) 23 (24) 25 (11)
Either+ 97 (29) 45 (45) 52 (22)
Characteristics of healthy individuals referred through public health clinics in
Santa Clara County, CA, USA who completed tuberculin skin test [TST],
QuantiFERON-TB GOLDH interferon-c release assay, and H. pylori serology.
1152 (91%) born in Latin America; TST: tuberculin skin test, +, $ 10mm
induration (includes 18 prior positives not retested); QFT (QuantiFERON-TB-
GOLDH including M. tuberculosis antigens ESAT6 and CFP10 and M. tuberculosis
antigen TB7.7; +: $0.35 IU/ml IFN-c difference over unstimulated well.
2Latent TB infection [LTBI]: either TST+ or QFT+ for analysis; 7 (2%) individuals
reported prophylactic TB treatment 3–34 years prior to enrollment. All factors
significant at p,0.05 (2-sided x2 test).
doi:10.1371/journal.pone.0008804.t001
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household contacts who remained disease-free. The study was
approved by the Institutional Review Boards of Stanford
University and the Aga Khan University Ethics Committee.
(3) TB challenge in cynomolgus macaques with and
without naturally acquired H. pylori infection. Stored
baseline sera, frozen gastric necropsy samples, and clinical
necropsy reports were obtained from a convenience sample of
45 cynomolgus macaques (Macaca fasicularis) (.4 years of age) used
in ongoing or completed low-dose TB challenge studies. All
monkeys included in our study had been challenged
endotracheally with 25 CFU of the Erdman strain of M.
tuberculosis. Monkeys were assessed clinically for at least eight
months post-challenge, and were classified as having active TB or
latent infection based on previously defined criteria [19].
Specifically, monkeys were classified as having active TB if they
had any clinical signs of disease, including weight loss, appetite
loss, cough, radiographic findings, elevated erythrocyte
sedimentation rate (ESR), or BAL or gastric aspirate that grew
M. tuberculosis after the first two months of infection. Monkeys were
classified as latent if they exhibited no signs of active disease (by the
measures described above) and had culture negative BAL and
gastric aspirate samples after 2 months of infection. These criteria
have been validated at necropsy in a large group of monkeys [20].
The Pittsburgh model has previously yielded approximately 50%
active and 50% latent disease post-challenge [19,20]. The
outcome is independent of gender, weight or age (between 4–10
years of age) in this model [20]. The animals were housed and
maintained in accordance with standards established in the
Animal Welfare Act and the Guide for the Care and Use of
Laboratory Animals. All procedures and protocols were approved
by the Institutional Animal Care and Use Committee (IACUC) of
the University of Pittsburgh.
Laboratory Methods
H. pylori infection in humans. The diagnosis of H. pylori
infection was ascertained by enzyme-linked immunosorbent assay
(ELISA). Per protocol, all samples were run in triplicate by
technicians blinded to the TB infection or outcome classification of
samples, and samples with different infection classifications were
intermixed on the same plates and run on the same days. Final
serologic interpretations were completed before samples were
linked to case records.
For the Northern California subjects, a high molecular weight
whole cell lysate ELISA antigen was derived from 2 Asian, 2
Mexican, and 2 US isolates of H. pylori with results interpreted
according to validated cut-offs, as previously described [2,21].
Because antibodies to H. pylori’s immunodominant CagA protein,
present in approximately 65% of H. pylori isolates, may be more
reliable in samples from developing countries [22,23], Pakistan
and Gambian samples were tested for IgG antibody response to
the orv220 fragment of H. pylori CagA (courtesy H. Kleanthous) as
previously described [24]. A sample was considered positive if
Figure 1. Samples recruited for H. pylori testing from Tuberculosis Case-Contact Studies. Blood samples were recruited for H. pylori
serology testing from the specimen banks of tuberculosis case- contact studies carried out in (A) The Gambia, West Africa (Ref. 13,16), and (B) Karachi,
Pakistan (Ref 14). Each study followed household members exposed to an active (index) case of tuberculosis for at least 2 years. Eligible samples were
from HIV-negative participants. Samples from Gambia were randomly selected in 2 groups to match household contacts by age and sex to index and
incident TB cases, respectively. LTBI: latent tuberculosis infection at baseline, defined as TST $10mm or ELISPOT $8 SFU (Gambia), or as TST $10mm
(Pakistan). Baseline characteristics are shown in Table S4.
doi:10.1371/journal.pone.0008804.g001
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optical density reading exceeded the mean + 3SD of 15 CagA
negative controls. Indeterminate samples (n = 24) were classified as
negative for analysis.
Measles antibodies. To establish baseline humoral re-
sponse, quantitative IgG antibody response to measles was
compared in a subset of samples from 100 culture-confirmed
Gambian TB patients and 100 age and sex-matched household
contacts with latent infection, using the Bioquant IgG ELISA (San
Diego, CA) with qualitative results interpreted according to
manufacturer’s criteria.
TB antigen-induced cytokine studies. We used the
QuantiFERON-TB-GOLDH (Cellestis, Ltd, Carnegie, Victoria,
Aus) assay to quantify stimulated PBMC IFN-c responses to
specific M. tuberculosis peptides as previously described [25].
Quantitative results, expressed as IU/ml, representing the
difference in IFN-c response to M. tuberculosis peptides or PHA
and a saline control for each subject, were transformed for
statistical analysis using the natural log base. Residual supernatants
from stimulated PBMCs were stored at 280uC and subsequently,
65 samples from adults were further assayed in a Luminex xMAP
200 platform using customized bead preparations (Beadlyte
Human 26-plex Multi-Cytokine, Millipore, Billerica, MA).
Concentrations for a standard reference curve were included on
each plate per manufacturer’s instructions. For each subject
cytokine concentrations in the unstimulated control well were
subtracted from TB specific responses, expressed as pg/ml.
H. pylori diagnostic procedures in monkeys. Frozen
serum samples obtained before M. tuberculosis challenge (N= 44)
or soon thereafter (1 sample obtained 33 days post infection) were
sent to Stanford University for ELISA. A rhesus-derived H. pylori
strain was employed for the ELISA antigen. In prior studies with
the rhesus model, this assay had an estimated sensitivity and
specificity against endoscopy or breath test of 96% and 88%
respectively [26]. Gastric tissue obtained at necropsy (n = 28
monkeys) and frozen at 280C for between 1 week and 22 months
(median 13.8 months), was shipped to U.C. Davis, fixed, and
processed in the laboratory of J. Solnick for H. pylori culture and
histopathology respectively as previously described [15].
Statistical Analysis
Statistical analysis was conducted using SAS v. 9.3. All statistical
tests were carried out at alpha set to 0.05 for a two-sided test. The
following analyses were conducted:
(1) IFN-c responses to TB antigens in Northern
Californians with and without H. pylori infection. To
evaluate whether concurrent H. pylori infection affects the
immune response to M. tuberculosis antigens, we compared
quantitative TB specific IFN-c responses stratified by H. pylori-
and latent M. tuberculosis infection. H. pylori infection was defined
by results of the whole cell lysate ELISA. We defined latent TB
infection (LTBI) presumptively as either M. tuberculosis specific
IFN-c response $0.35 IU/ml or TST result $10 mm, with no
signs or symptoms of active TB. A Generalized Linear Model
was used to compare group means accounting for the
interaction of H. pylori and LTBI as well as to adjust for
potential confounders (age, sex, and country of origin); p-values
are based on the F-test (Fisher’s LSD) for pre-planned contrasts
(e.g. H. pylori effect within LTBI). For multiplex-cytokine
analysis, Principal Components Analysis [27] was performed
with the correlation matrix composed of six variables found to
discriminate by Wilcoxon’s test between 40 latently infected and
25 controls (Tables S1 and S2), and components having
Eigenvalue .1 were selected to compute summary component
scores for each subject using eigenvector coefficients.
Comparison of H. pylori prevalence in human tuber-
culosis case-contact cohorts. We compared rates of H. pylori
CagA infection in index TB cases, incident TB cases, and
household contacts known not to have progressed to active disease
during follow-up (nonprogressors). Logistic regression was used to
evaluate factors associated with H. pylori infection in each cohort
and in the cohorts combined. Odds ratios and 95% confidence
intervals of H. pylori infection in nonprogressors compared to
prevalent or incident TB cases were computed with adjustment for
age, gender, latent M. tuberculosis infection at baseline, and cohort
location (Pakistan or The Gambia). Goodness of fit was evaluated
using the Hosmer-Lemeshow test [28]. A generalized nonlinear
mixed model with random intercept (SAS GLIMMIX) was used to
examine results with adjustment for household membership.
M. tuberculosis challenge in cynomolgus macaques
with and without naturally acquired H. pylori infection.
Monkeys were categorized clinically by 6–8 months after aerosol
infection as having active tuberculosis or latent infection. H. pylori
infection in monkeys was defined as a positive serologic test for H.
pylori prior to M. tuberculosis infection. Because gastric tissue had
not been obtained or conserved for the purposes of H. pylori
histology or culture, negative results to these two tests were not
considered reliable for determining presence or absence of
infection. Relative risk and 95% confidence intervals of active
vs. latent tuberculosis in H. pylori infected versus uninfected
monkeys was computed.
Results
IFN-c Responses to TB Antigens in Northern Californians
with Concurrent H. pylori Infection
Of 339 subjects (113 children and 226 adults), 97 (29%)
individuals met criteria for latent TB infection, including 82 (24%)
individuals with TST induration $10mm and 48 individuals
(14%) with TB specific antigen induced IFN-c $0.35 IU/ml. A
total 242 (71%) individuals were negative by both criteria and
classified as not latently infected. Of subjects classified as latently
infected, 45 (46%) were H. pylori seropositive as compared with 52
(22%) of the 242 subjects classified as LTBI negative (p,0.001).
Compared to 52 latently infected subjects without H. pylori
infection, mean IFN-c responses to specific TB antigens were
approximately 1.5 fold greater in 46 subjects with concurrent H.
pylori infection (Figure 2A), and this difference remained
significant after adjusting for age, sex and country of birth
(p = 0.04, ANOVA). In contrast, IFN-c responses did not vary
significantly with respect to H. pylori infection among 242 LTBI-
negatives (p = 0.40), indicating an interaction effect between H.
pylori and LTBI (p = 0.03, ANOVA). These results were similar
when restricting the definition of LTBI to TST positivity only (data
not shown).
The effect on IFN-c responses to M. tuberculosis antigens of past
exposure to Hepatitis A virus, a picornavirus infection with
epidemiologic patterns similar to those of H. pylori [29] was similar
to that for H. pylori (Figure 2B). In fact, in a 3-way interaction
model, having H. pylori infection, HAV and LTBI was associated
with greater IFN-c responses to TB than having either infection
singly with LTBI (Figure 2C).
In the 65 adults (40 with LTBI and 25 without) tested by 26-
multiplex cytokine assay (Table S1), IL2, TNF-a, CXCL-10 (IP10),
IL-13 and IL-5, as well as IFN-c, were differentially detected in
latently infected vs. uninfected subjects (Table S2). Within the 40
latently infected, samples from the 23 subjects with concurrent H.
pylori infection had higher summary measures of Th-1-type (IFN-c,
IL2, TNF-a, CXCL-10) cytokine responses to TB antigens
H. pylori and Tuberculosis
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(p = 0.03, Wilcoxon) than did the 17 H. pylori seronegative
(Figure 3a and b; Table S3). Overall, 9 (82%) of 11 subjects
classified as having dominant Th1-type cytokine responses to M.
tuberculosis infection were H. pylori seropositive (p = 0.05 Fishers
exact test).
Comparison of H. pylori Sero-Prevalence in Human
Tuberculosis Case-Contact Cohorts
Among a total 670 samples tested, 425 (63%) were H. pylori
seropositive according to the CagA assay, including 59/121
(49%) of Karachi, Pakistan and 366/549 (67%) of Gambian
household contacts (p = 0.0002, supplemental Table S5). H. pylori
seroprevalence varied significantly by TB outcome classification
(Table 2, and Table S6 for results by cohort). Compared to 513
household contacts who remained disease-free throughout
follow-up, the 120 TB cases were about K as likely to be H.
pylori CagA positive (AOR: 0.55 (95% CI 0.36–0.83, p = 0.005),
while seroprevalence was not different between nonprogressors
and 37 incident TB cases (AOR: 1.35 [95% CI 0.65–3.0),
p = 0.44). These results were similar when restricted to samples
from 466 subjects considered latently infected, as well as when
accounting for household membership in a random intercept
nonlinear mixed model.
To explore whether the diminished antibody responses to H.
pylori in prevalent TB patients might result from immune deficits
associated with having active disease, we evaluated measles
antibody responses in 100 Gambian culture-confirmed TB cases
and 100 age- and sex-matched latently infected nonprogressors.
Equal numbers of cases and contacts responded to a measles IgG
antibody test (90% and 88% respectively) with virtually identical
mean optical density values (Figure S1), suggesting that active TB
disease did not cause a diminution of humoral responses.
Figure 2. IFN-c responses to TB antigens are amplified in concurrently infected subjects. A: TB antigen induced (24 hour) IFN-c responses
in 97 subjects classified as TB infected [LTBI] and 242 subjects classified as without LTBI, stratified by H. pylori infection status; p-values denote age
and sex-adjusted difference within LTBI classification (ANOVA). B. panel A obtained by substituting results of Hepatitis A virus total IgG antibody
response [HAV] for H. pylori response; C.mean IFN-c levels within 97 LTBI+ by H. pylori and HAV antibody test results; p-values denote contrast within
each infection grouping. LTBI+: TST$10 mm induration or QuantiFERON-TB GOLDH positive ($0.35 IU/ml difference over unstimulated well); LTBI2:
TST,10mm and QuantiFERON-TB GOLDH-,0.35 IU/ml; error bars represent 95% confidence interval of the least squares means.
doi:10.1371/journal.pone.0008804.g002
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Figure 3. Concurrent H. pylori infection is associated with Th1+/Th22 type profile. A. Scatterplot of principal component scores for 40
adults with latent TB infection (either QuantiFERON-TB GOLDH or TST positive) obtained after linear transformation with eigenvector coefficients.
Vertical-axis: 1st component (eigenvalue 2.6), which is largely explained by IFN-c and IL-2, and to a lesser extent IP-10 and TNF-a. Horizontal axis: 2nd
PC (eigenvalue 1.5), characterized by loading of IL-13 and IL-5 and negative correlations with the four inflammatory markers. Red circles: 23 H. pylori
infected; Black circles: 17 H. pylori seronegative. Reference lines denote quadrants centered on 0; B. comparison of median composite Th1 and Th2
component scores; p-values computed by Wilcoxon’s 2-sided median test.
doi:10.1371/journal.pone.0008804.g003
Table 2. Factors associated with H. pylori CagA infection in tuberculosis case-contact cohort samples (adjusted odds ratio).
Factor Reference All samples (n =670) p-value Latent TB (n =466) p-value
Age 10 y 0.87 (0.79–0.97) 0.01 0.93 (0.83–1.1) 0.26
Sex Female 0.97 (0.70–1.4) 0.88 0.94 (0.64–1.4) 0.74
LTBI Uninfected 0.79 (0.55–1.2) 0.22
TB Outcome Nonprogressor 1.0 1.0
Prevalent (Index) Case 0.55 (0.36–0.83) 0.005 0.51 (0.32–0.8) 0.003
Incident TB case 1.35 (0.63–2.9) 0.44 1.3 (0.53–3.2) 0.56
Pakistan TBCC Gambia 0.46 (0.31–0.69) ,0.001 0.37 (0.23–0.59) ,0.001
H-L x2 10.02 (p = 0.25) H.L.x2 3.6 (p = 0.91)
Nonprogressor: household contact of TB case remaining disease free at least 2 years from baseline; Prevalent (Index) case: untreated active TB case at baseline; Incident TB
case: household contact developing active TB 3–49 months from baseline (see methods).; H.L.: Hosmer-Lemeshow test.
doi:10.1371/journal.pone.0008804.t002
H. pylori and Tuberculosis
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TB Challenge in Cynomolgus Macaques with and without
Naturally Acquired H. pylori Infection
Of the 45 monkeys, 4 monkeys had indeterminate H. pylori
results by the rhesus-based H. pylori ELISA and were excluded
from the analysis. Among the remaining 41 monkeys, 30 (73.2%)
were seropositive and 11 (26.8%) were seronegative for H. pylori.
Although, as expected, culture yields in seropositive monkeys were
low due to tissue autolysis and storage, all 6 H. pylori culture-
positive monkeys were positive by serology, as were 4 of 6 H. pylori
histology positive monkeys. Of the 30 monkeys with positive H.
pylori serology (Table 3), only 5 (16.7%) developed active
tuberculosis whereas 6 (54.6%) of the 11 negative monkeys
developed active tuberculosis (relative risk 0.31, 95% CI 0.12–
0.80, p = 0.04, Fisher’s Exact test).
Discussion
Humans are colonized by complex, site-specific microbial
communities that are increasingly implicated in human health
and disease in unexpected ways. In some cases, microbial
communities are thought to modulate non-infectious diseases,
such as obesity [30], asthma and autoimmune diseases [31].
Viewed broadly, the human microbiota may be a major regulator
of the immune system modulating not only inflammatory disorders
(the ‘‘hygiene hypothesis’’), but responses to infectious challenges
as well [32]. Because they continuously stimulate non-specific
responses in the host, chronic mucosal infections may be
particularly important in this regard.
The high prevalence of H. pylori in populations where TB and
other lethal infections remain endemic suggests the host-pathogen
interplay of these infections has co-evolved. In this report, we have
presented evidence from three different study designs that H. pylori
infection affects response to M. tuberculosis. First, we found in a
cross-sectional human study that H. pylori is associated with
enhanced IFN-c and Th1-like responses to specific TB antigens.
Second, in baseline samples from two high risk human tuberculosis
case-contact cohorts, we observed that infected household contacts
who maintain latency over two years are significantly more likely
to have concurrent H. pylori infection than are TB cases, although
seroprevalence was not different in incident TB cases. Finally, in a
retrospective cohort study of low-dose M. tuberculosis challenge
monkeys, we observed that H. pylori-infected animals are
significantly less likely to develop active disease than are uninfected
animals. While further studies are indicated, taken together, these
lines of investigation offer a heretofore unexplored role for
infections like H. pylori to alter the outcome of M. tuberculosis
infection.
We propose two potential models by which H. pylori could
promote a protective immune response to TB infection. In the first
model, an infection in early childhood could permanently
differentiate immature T-cells to a Th1-like phenotype. Such a
‘‘hygiene hypothesis,’’ has been advanced for hepatitis A [33], and
would favor past as well as ongoing infections contributing to a
state of heightened immunity. Alternatively, H. pylori might induce
a bystander effect with continuous inflammation and T-cell
signaling enhancing the host’s innate response to a spectrum of
infectious challenges. Similar effects have been demonstrated with
c-herpesvirus in mice challenged with Listeria monocytogenes and
Yersinia pestis [34]. These authors speculate that non- specific
induction of interferon-c (IFN-c) activates macrophages and
primes innate defenses to other infections. We did not test for
antibodies to HAV or herpesviridae in the human tuberculosis
case-contact cohorts. Because these exposures are likely to be very
common in populations where both H. pylori and M. tuberculosis
infections are common, more systematic sampling designs may be
needed to adequately explore interaction effects.
H. pylori naturally infects macaques. The fact that we were able
to replicate a significant association of H. pylori infection with latent
outcomes in the Pittsburgh cynomolgus monkey TB challenge
model [19,35] offers new opportunities to explore mechanistic
arguments in depth. Because the present work is based on a
convenience sample from the Pittsburgh laboratory, repeated
measures of immunologic responses and clinical progression were
not investigated. More systematic experimental study designs,
including prospective studies utilizing H. pylori challenge, are
planned.
The accuracy of H. pylori serology in the developing world is
suboptimal [22]. Although the CagA assay may be more reliable
for comparing different populations, misclassification of H. pylori
infection status still cannot be excluded. Typically, misclassifica-
tion tends to yield a null result unless, for some reason, cases and
controls respond differently to the assay. We speculated that TB
cases might have weakened antibody responses, causing us to have
a spurious result. However, the fact that measles antibody titers
were robust and virtually the same in Gambian TB cases and age
and sex-matched latently infected contacts argues against this
explanation of results. That H. pylori seroprevalence did not differ
between incident TB cases and nonprogressors in our cohort
samples, while limiting our conclusions, can also reflect artifacts of
the TBCC study model, including the low numbers of secondary
cases, ascertainment differences or biases, as well as limitations of
H. pylori serologic detection in this setting. In both cohorts, most
cases of TB were identified at an initial screening visit, and M.
tuberculosis infection at baseline was a relatively weak predictor of
progression [14,36]. Thus, continued work with longitudinal
cohorts may benefit from multi-site study designs incorporating
additional H. pylori diagnostics as well as other prognostic
biomarkers of immune response to TB exposure and infection.
M. tuberculosis specific antigen interferon-c release assays are
important noninvasive tools for measuring immunogenicity of the
heterologous prime boost T-cell based vaccines for TB [37,38].
Our results raise the possibility that H. pylori infection and other
Th-1 modifying infections present in the host background can alter
these profiles. As our results also do not exclude the possibility that
M. tuberculosis modifies the host response to H. pylori infection,
PBMC responses to TB antigens pre- and post- antibiotic
treatment for H. pylori would help shed light on the specificity of
our findings, including reversibility. In vitro studies examining
possible mechanisms of T-cell cross reactivity, such as effect of H.
pylori antigen on M. tuberculosis antigen presenting cells and MHC
expression, are also needed.
Why only 10% of infected individuals succumb to tuberculosis
remains one of the most vexing public health questions–one which
Table 3. Seroprevalence of H. pylori infection in 41 Pittsburgh
cynomolgus macaques by outcome of TB challenge at 6–8
months.
H. pylori infection Active TB Latent TB Total
Infected 5 (17) 25 (83) 30 (73)
Uninfected 6 (55) 5 (45) 11 (27)
Total 11 30 41
Relative risk of active TB in H. pylori infected: 0.31 (0.12–0.80)
p= 0.04 (Fisher’s exact test)
doi:10.1371/journal.pone.0008804.t003
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the one-pathogen-one-disease paradigm is ill-equipped to answer.
While preliminary, our work suggests that one factor contributing
to the clinical outcome of TB infection may be a concurrent
chronic infection. The hypothesis that the human microbiome has
evolved to provide context-specific competitive risk advantages to
the host [39] also raises the intriguing possibility that our
microbiota can be manipulated to modulate disease risk from M.
tuberculosis, as well as other common human pathogens [40].
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and 100 latently infected household contacts. Ref. line: positive cut-
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